Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013 American Academy of Neurology Annual Meeting

JERUSALEM--(BUSINESS WIRE)--

Teva Pharmaceutical Industries Ltd. (TEVA) today announced that 15 abstracts highlighting study results for Parkinsons disease (PD) and relapsing-remitting multiple sclerosis (RRMS) will be presented during the 65th American Academy of Neurology (AAN) annual meeting in San Diego, Calif., March 16-23, 2013. New data for AZILECT (rasagiline tablets), an MAO-B inhibitor for the treatment of PD, will be presented as part of the meetings Emerging Science program (formerly known as Late-Breaking Science) on Wednesday, March 20th at 5:45pm PST.

We are pleased with the variety of topics and quality of research results that will be presented at AAN this year, said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries Ltd. Tevas legacy in CNS is grounded in our commitment to ongoing collaboration with academia, medical institutions, and patient advocacy groups to find innovative solutions for patients who live with chronic and debilitating diseases, such as RRMS and Parkinsons disease.

Featured presentations include:

Platform Presentation/Poster Session Details:

AZILECT

COPAXONE

Laquinimod

About Azilect

AZILECT (rasagiline tablets) is indicated for the treatment of the signs and symptoms of Parkinson's disease (PD) both as initial therapy alone and to be added to levodopa later in the disease.

See the rest here:
Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013 American Academy of Neurology Annual Meeting